I would agree with your views but it’s difficult to digest FDA would go against 9-1 vote. A decision that would cost billions of dollars, probably few jobs and as a consequence, lot of regenerative medicine companies would also take a big hit. Rejection of Ryoncil would undoubtedly impact lot of other start up bio. Many in this industry will struggle to raise money. They could face harsh criticism and I don’t think they are immune to it.
I would agree with your views but it’s difficult to digest FDA...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |